Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;7(Suppl 1):S24.
doi: 10.21037/atm.2019.01.74.

The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

Philip Friedlander  1
Affiliations
Editorial

The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

Philip Friedlander. Ann Transl Med. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Philip Friedlander: Advisory board for Regeneron Pharmaceuticals and Array Biopharma. Consultant for Aspyrian Therapeutics. Stock ownership in Incyte Pharmaceuticals, Clovis, Allergan, and Marrimack Pharmaceuticals.

Comment on

References

    1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206. 10.1200/JCO.2009.23.4799 - DOI - PMC - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-92. - PMC - PubMed
    1. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6 Suppl 1:S11-4. - PubMed
    1. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51. 10.1200/JCO.1999.17.9.2745 - DOI - PubMed
    1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. 10.1056/NEJMoa1003466 - DOI - PMC - PubMed